Maud Tusseau

Maud Tusseau

Auto-generated profile, based on publicly available information

Maud Tusseau

Hospices Civils de Lyon, National HHT Reference Center and Genetics Department, Bron, France (M.T., S.G., G.L., A.G., S.D.-G.).

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
MJMarie Jeanpierre
Marie Jeanpierre
JCJade Cognard
Jade Cognard
MTMaud Tusseau
Maud Tusseau
QRQuentin Riller
Quentin Riller
LBLinh-Chi Bui
Linh-Chi Bui
AMAnne-Laure Mathieu
Anne-Laure Mathieu
An exome sequencing strategy employed to identify pathogenic variants in patients with pediatric-onset systemic lupus or Evans syndrome resulted in the discovery of six novel monoallelic mutations in PTPN2. PTPN2 is a phosphatase that acts as an essential negative regulator of the JAK/STAT pathways. All mutations led to a loss of PTPN2 regulatory function as evidenced by in vitro assays and by hyperproliferation of patients’ T cells. Furthermore, patients exhibited high serum levels of inflammatory cytokines, mimicking the profile observed in individuals with gain-of-function mutations in STAT factors. Flow cytometry analysis of patients’ blood cells revealed typical alterations associated with autoimmunity and all patients presented with autoantibodies. These findings further supported the notion that a loss of function in negative regulators of cytokine pathways can lead to a broad spectrum of autoimmune manifestations and that PTPN2 along with SOCS1 haploinsufficiency constitute a new group of monogenic autoimmune diseases that can benefit from targeted therapy.

12 January 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
MTMaud Tusseau
Maud Tusseau
CDClaire Desvignes
Claire Desvignes
GBGuilaine Boursier
Guilaine Boursier
CFClémentine Fort
Clémentine Fort
CDClémence David
Clémence David
ABAlexandre Belot
Alexandre Belot
Early-onset systemic lupus erythematosus (SLE) is frequently associated with a more severe phenotype and may be linked to monogenic causes in at least 10% of all juvenile SLE cases. Recent advances in immunogenetics have identified Mendelian variants linked to inborn errors of immunity, underlying SLE. Toll-like receptor 7 (TLR7), an endosomal RNA sensor, has emerged as a key contributor to lupus pathogenesis through aberrant activation. We report a novel P435S gain-of-function (GOF) variant in TLR7 identified in a female patient presenting with early-onset SLE, recurrent infection, and neuroinflammatory features. Functional assays demonstrated the gain-of-function effect, confirming its pathogenicity and supporting its role in disease onset and progression. To further define the clinical spectrum of TLR7 GOF-associated disease, we conducted a systematic review of 11 additional reported cases, highlighting shared and divergent phenotypic features. These findings expand the understanding of TLR7-mediated autoimmunity and underscore the importance of genetic screening in early-onset SLE with atypical features.

20 November 2025 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
SWSophie Wolfgramm
Sophie Wolfgramm
SASara Alehashemi
Sara Alehashemi
MWMartin Wendlandt
Martin Wendlandt
FTFranziska G. Thiel
Franziska G. Thiel
AJAdriana A. de Jesus
Adriana A. de Jesus
RGRaphaela Goldbach-Mansky
Raphaela Goldbach-Mansky
Proteasome-associated autoinflammatory syndromes (PRAAS) include a group of autoinflammatory interferonopathies caused by 20S proteasome dysfunction. We characterised pathomechanisms and treatment responses of patients with a de novo, dominant-negative (DN)-proteasome subunit beta type-8 (PSMB8) variant. Patients with the DN-PSMB8 p.G209R variant encoding a mutant β5i subunit of the 20S immunoproteasome were evaluated. Interferon biomarkers, proteasome activity, structural modelling, and proteotoxic stress responses were assessed. Patients' T cells underwent integrated transcriptomic and proteomic profiling to characterise immune dysregulation, proteotoxic stress responses, mitochondrial function, and type I interferon (IFN-I) associated stress signalling. Patients with DN-PRAAS presented with early-onset systemic inflammation, panniculitis, cytopenias, infections, and porto-sinusoidal vascular liver disease (PSVD), indicating broader immune dysfunction that partially responds to Janus kinase inhibition and/or interferon-α/β receptor blockade (anifrolumab). Mechanistically, the PSMB8 p.G209R variant caused steric hindrance that impaired β5i propeptide processing and final 20S proteasome formation, resulting in intracellular protein aggregation, impaired mitochondrial metabolism, and altered neutral lipid processing. The IFN-I signature of patients' T cells was reduced by blockade of 2 integrated stress response (ISR)-regulating kinases, protein kinase R (PKR) and general control nonderepressible 2 (GCN2), and by Janus kinase signalling. The DN-PSMB8 p.G209R variant broadens the clinical and mechanistic PRAAS spectrum by causing 20S proteasome maturation arrest and uncovering a convergence between mitochondrial dysfunction and the ISR. Our findings implicate cytopenia in a pattern of vascular pathology, including PSVD of the liver. We further identify PKR and GCN2 as key mediators of maladaptive IFN-I responses and potential therapeutic targets.

10 March 2026 in Journal of Experimental Medicine
Verified
Journal Article
Open access
CDClémence David
Clémence David
TWTifenn Wauquier
Tifenn Wauquier
ABAlix de Becdelièvre
Alix de Becdelièvre
CLCamille Louvrier
Camille Louvrier
MTMaud Tusseau
Maud Tusseau
MFMarie-Louise Frémond
Marie-Louise Frémond
COPA syndrome is a rare monogenic autoinflammatory disease due to heterozygous mutations in COPA, encoding the coatomer subunit α. COPA syndrome demonstrates phenotypic overlap with STING-associated vasculopathy with onset in infancy (SAVI), the latter due to gain-of-function mutations in STING1. Indeed, STING activation is a key driver of the pathogenesis of COPA syndrome, and a recent report suggested that the presence of the common HAQ STING allele confers complete protection against the development of clinical disease in the context of pathogenic heterozygous mutations in COPA. Given the potential significance of this result for patient management, we investigated the STING HAQ haplotype status of a separate cohort of individuals segregating pathogenic mutations in COPA. In doing so, we ascertained five HAQ-negative, clinically asymptomatic individuals aged 30, 39, 39, 42, and 43 years at last evaluation, and an HAQ-positive male with kidney disease that we consider most likely attributable to the recurrent R233H mutation in COPA. Our findings challenge the suggestion that STING haplotype status is the sole determinant of clinical penetrance in COPA syndrome.

1 August 2026 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
ADAgnes Desroches-Castan
Agnes Desroches-Castan
LBLéa Beurier-Soulat
Léa Beurier-Soulat
MTMaud Tusseau
Maud Tusseau
FCFlorence Coulet
Florence Coulet
VAValentin Azemard
Valentin Azemard
SBSabine Bailly
Sabine Bailly
BACKGROUND: GDF2 (encoding BMP9) variants have been described in pulmonary arterial hypertension (PAH) and hereditary hemorrhagic telangiectasia (HHT), as well as a few BMP10 variants in PAH. The purpose of the present study was to develop a functional assay capable of discriminating benign from pathogenic variants and to characterize the underlying molecular mechanisms responsible for their loss of function. METHODS: We developed a single-step functional assay in which C2C12 cells stably expressing a BMP (bone morphogenetic protein)-responsive element upstream of a firefly luciferase reporter would be stimulated by the autocrine secretion of BMP9 or BMP10 variants produced by transfected expression plasmids. RESULTS: Using this functional assay, we reclassified all GDF2 variants and 2 out of 5 BMP10 variants identified in patients with PAH as likely pathogenic. In contrast, only 2 of the 4 GDF2 variants identified in suspected patients with HHT were found to be likely pathogenic; nevertheless, none of the patients met the diagnostic criteria for hereditary hemorrhagic telangiectasia. We also showed, using ELISAs and Western blots, that the loss of function of GDF2 and BMP10 variants was mostly due to altered processing (folding/stability defects). Moreover, we found that loss-of-function GDF2 variants impaired the secretion of BMP10, suggesting a potential dominant-negative mechanism. CONCLUSIONS: We developed a functional assay for GDF2 and BMP10 variants, enabling the reclassification of variants of unknown significance. Together, this study further supports the involvement of GDF2 and BMP10 as predisposing genes in PAH. This single-step assay will be transferable to clinical genetic laboratories and will improve diagnosis of patients with PAH and HHT.

9 April 2026
Verified
Thesis
Closed access
MTMaud Tusseau
Maud Tusseau
Le lupus érythémateux systémique (LES) est une maladie auto-immune systémique chronique caractérisée par une atteinte multiviscérale et une grande hétérogénéité clinique. La présence d’anticorps antinucléaires constitue un marqueur biologique central pour le diagnostic. Un excès d’interféron de type I est également retrouvé chez la majorité des patients et joue un rôle clé dans la physiopathologie de la maladie. Le LES est considéré comme une pathologie multifactorielle, en raison de la contribution combinée de facteurs génétiques et environnementaux. Néanmoins, de rares formes monogéniques ont été rapportées, liées à des variants ponctuels dans un seul gène, notamment chez des patients présentant un début précoce des symptômes. Afin de mieux comprendre les bases génétiques du lupus pédiatrique, nous avons mené une étude sur une cohorte de patients atteints de LES à début pédiatrique (avant 18 ans). Par une approche de Sanger, nous avons tout d’abord identifié un premier cas de lupus monogénique secondaire à un nouveau variant de DNASE1L3. Ce variant, suspecté d’altérer l’épissage, a été fonctionnellement exploré par une approche minigene. Un séquençage de l’exome a ensuite été réalisé chez 263 individus issus de 172 familles distinctes. Au total, un diagnostic moléculaire compatible avec le tableau clinique a pu être établi chez 17 patients, soit environ 10 % de la cohorte. Parmi eux, nous avons mis en évidence des variants pathogènes ou probablement pathogènes dans des gènes déjà connus dans les formes monogéniques de lupus, notamment un nouveau variant de C1QA, ainsi que des variants dans d’autres gènes compatibles avec un phénotype lupique tels que COPA, ADAR, TLR7, IKZF3, RELA, PTPN11 et SERPING1. L’analyse a également révélé des variants dans des gènes associés à des déficits immunitaires (IRAK4, USB1), des maladies auto-inflammatoires (PSTPIP1) ainsi que dans des gènes inattendus comme ETV6 et MAN1B1, suggérant l’implication de voies biologiques jusque-là non reconnues dans la physiopathologie du lupus. Nous avons également identifié des variants dans des gènes candidats et contribué à la caractérisation fonctionnelle de nouveaux gènes impliqués dans des formes monogéniques d’auto-immunité, notamment SOCS1, PTPN2 et DOCK11. Enfin, nous avons également initié des travaux portant sur des variants somatiques du gène SOCS1, identifiés dans un contexte de cancers hématologiques, montrant des variants faux-sens pathogènes. Ces résultats démontrent tout d’abord l’intérêt d’un séquençage pangénomique pour le diagnostic des formes pédiatriques de LES, en particulier pour les formes très précoces ou syndromiques où l’on retrouve une cause génétique dans près d’un tiers des cas. le lupus représente un phénotype autoimmun systémique commun à des altérations moléculaires hétérogènes Pour les patients, la découverte de ces formes monogéniques permet non seulement de préciser le diagnostic, mais ouvre également la voie à des thérapies personnalisées et ciblées, potentiellement plus efficaces et moins toxiques que les immunosuppresseurs classiques. Enfin, l’étude de ces formes rares contribue à une meilleure compréhension des mécanismes de tolérance immunitaire et à l’identification des facteurs moléculaires régulateurs de l’auto-immunité chez l’Homme.